



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

February 9, 2026

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs / Madam,

Sub: Outcome of Board Meeting – Unaudited Financial Results for the quarter and nine months ended December 31, 2025.

Ref.: Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025, which were approved by the Board of Directors of the Company at their Meeting held today i.e., February 9, 2026, that commenced at 3.00 p.m. and concluded at 4.45 p.m.

Also please find enclosed herewith the Limited Review Report issued by the Statutory Auditors, B S R & Co. LLP, in respect of the said Unaudited Financial Results.

Request you to please take the above on record.

Thanking you,

Yours truly,
For **Pfizer Limited**

Prajeet Nair
Director – Corporate Services & Company Secretary

Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Sreeja Marar

Partner

Mumbai

09 February 2026

Membership No.: 111410

UDIN:26111410JDNYDT2380



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December 2025

(₹ in crore except earnings per share)

	Particulars	3 months ended 31/12/2025	Preceding 3 months ended 30/09/2025	Corresponding 3 months ended 31/12/2024	Year to date figures for Nine months ended 31/12/2025	Year to date figures for Nine months ended 31/12/2024	Previous year ended 31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	645.03	642.34	537.99	1,890.42	1,689.44	2,281.35
	(b) Other income	38.21	41.85	42.76	147.23	127.67	172.25
	Total income	683.24	684.19	580.75	2,037.65	1,817.11	2,453.60
2	Expenses						
	(a) Cost of materials consumed	67.78	70.00	67.31	226.47	201.70	272.34
	(b) Purchases of stock-in-trade	145.15	221.27	104.99	490.70	373.23	512.75
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	11.84	(63.32)	24.26	(53.22)	33.04	25.36
	(d) Employee benefits expense	100.30	94.67	96.29	290.79	288.42	371.33
	(e) Finance costs	1.99	2.13	1.51	7.37	5.72	8.41
	(f) Depreciation and amortization expense	14.26	14.28	14.80	42.95	44.39	60.79
	(g) Other expenses	91.77	89.79	99.15	267.54	280.32	359.34
	Total expenses	433.09	428.82	408.31	1,272.60	1,226.82	1,610.32
3	Profit before tax and exceptional items (1 - 2)	250.15	255.37	172.44	765.05	590.29	843.28
4	Exceptional items (Refer Note 4 & 5)	(58.20)	-	-	(58.20)	-	172.81
5	Profit before tax (3 + 4)	191.95	255.37	172.44	706.85	590.29	1,016.09
6	Tax expense						
	(a) Current tax	58.00	65.49	50.10	190.88	165.04	264.10
	(b) Deferred tax	(7.89)	0.86	(5.26)	(6.64)	(11.41)	(15.61)
7	Net profit for the year (5 - 6)	141.84	189.02	127.60	522.61	436.66	767.60
8	Other comprehensive income						
	(a) Items that will not be reclassified subsequently to profit or loss	2.51	(1.22)	(0.72)	0.06	(2.15)	0.99
	(b) Income tax related to items that will not be reclassified to profit or loss	(0.64)	0.31	0.18	(0.02)	0.54	(0.25)
	Other comprehensive income, net of taxes	1.87	(0.91)	(0.54)	0.04	(1.61)	0.74
9	Total comprehensive income for the period / year (7 + 8)	143.71	188.11	127.06	522.65	435.05	768.34
10	Paid-up equity share capital (Face value per share ₹10)	45.75	45.75	45.75	45.75	45.75	45.75
11	Other equity						4,171.66
12	Earnings per share - Basic and Diluted (of ₹10/- each) #						
	Computed on the basis of net profit for the year	31.01	41.32	27.89	114.24	95.44	167.79

Earnings per share - Basic and Diluted before Exceptional items

*Not annualised

CIN: L24231MH1950PLC008311

Email ID: contactus.india@pfizer.com

Website: www.pfizerindia.co.in

NOTES:

1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on February 09, 2026.
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
3. The financial results for the quarter and nine months ended December 31, 2025 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - www.pfizerltd.co.in
4. Exceptional items of ₹58.20 crore for the quarter and nine months ended December 31, 2025 include:
 - a) During the quarter, the Company has entered into an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium. The charge of ₹39.58 crore includes personnel separation cost of field force and marketing teams as a result of the said arrangement and also includes personnel separation cost for other support functions.
 - b) Effective 21 November 2025, the Government of India has consolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the 'New Labour Codes'. The Company has carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by ₹18.62 crore. The incremental impact is primarily due to change in wage definition. Considering the materiality and non-recurring nature of this impact, the Company has accounted such incremental impact under Exceptional items in the financial results for the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.
5. Exceptional Items for the Year ended March 31, 2025 relates to Net gain of ₹172.81 crore (net of carrying value of ₹31.75 crore and cost to sell - Premium and other charges ₹59.84 crore, net of recovery) on account of assignment of Lease of MIDC Land and Sale of Building constructed on such land.
6. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
7. The Company does not have any subsidiary company or associate company or joint venture company as at December 31, 2025.

For Pfizer Limited



Meenakshi Nevatia
Managing Director

February 09, 2026